nach oben

Die Pathologie

Erschienen in:

16.10.2017 | Aderhautmelanom | Schwerpunkt: Tumoren der Sinnesorgane

Okuläre Melanome

Ein „Update“

verfasst von: H. Kalirai, P. L. Müller, D. Jaehne, Prof. Dr. S. E. Coupland

Erschienen in: Die Pathologie | Ausgabe 6/2017

Einloggen, um Zugang zu erhalten

Zusammenfassung

Das Melanom ist der häufigste primäre Tumor des Auges im Erwachsenenalter. Etwa 95 % der okulären Melanome entstehen intraokular in der Uvea (d. h. Iris, Ziliarkörper und Chorioidea), wohingegen die verbleibenden 5 % in der Konjunktiva lokalisiert sind. Obgleich allgemein angenommen wird, dass sich uveale und konjunktivale Melanome aus Melanozyten entwickeln, unterscheiden sich die beiden Entitäten sowohl klinisch als auch biologisch. Darüber hinaus sind okuläre Melanome von den häufigeren Melanomen der Dermis abzugrenzen. Vor kurzem wurden große Fortschritte im Verständnis der zugrunde liegenden Pathophysiologie erzielt. Fortschritte auf molekularer Ebene haben die Prognoseabschätzung und die Identifizierung von therapeutischen Angriffspunkten v. a. für das uveale Melanom verbessert. Dieser Artikel zielt darauf ab, aktuelle Fortschritte bei der molekularen Charakterisierung von uvealen und konjunktivalen Melanomen zu diskutieren und deren Einsatzmöglichkeiten in der Entwicklung personalisierter Therapiestrategien aufzuzeigen.

Damato BE, Coupland SE (2012) Differences in uveal melanomas between men and women from the British Isle. Eye (Lond) 26(2):292. https://doi.org/10.1038/eye.2011.272 CrossRef

Caines R, Eleuteri A, Kalirai H, Fisher AC, Heimann H, Damato BE, Coupland SE, Taktak AF (2015) Cluster analysis of multiplex ligation-dependent probe amplification data in choroidal melanoma. Mol Vis 21:1–11PubMedPubMedCentral

Woodman SE (2012) Metastatic uveal melanoma: biology and emerging treatments. Cancer J 18(2):148–152CrossRefPubMedPubMedCentral

Damato B, Duke C, Coupland SE, Hiscott P, Smith PA, Campbell I, Douglas A, Howard P (2007) Cytogenetics of uveal melanoma: a 7-year clinical experience. Ophthalmology 114(10):1925–1931CrossRefPubMed

Damato B, Eleuteri A, Taktak AF, Coupland SE (2011) Estimating prognosis for survival after treatment of choroidal melanoma. Prog Retin Eye Res 30(5):285–295CrossRefPubMed

Jehs T, Faber C, Juel HB, Bronkhorst IH, Jager MJ, Nissen MH (2014) Inflammation-induced chemokine expression in uveal melanoma cell lines stimulates monocyte chemotaxis. Invest Ophthalmol Vis Sci 55(8):5169–5175CrossRefPubMed

Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R (1996) Prognostic implications of monosomy 3 in uveal melanoma. Lancet 347(9010):1222–1225CrossRefPubMed

Sisley K, Cottam DW, Rennie IG, Parsons MA, Potter AM, Potter CW, Rees RC (1992) Non-random abnormalities of chromosomes 3, 6, and 8 associated with posterior uveal melanoma. Genes Chromosomes Cancer 5(3):197–200CrossRefPubMed

White VA, Chambers JD, Courtright PD, Chang WY, Horsman DE (1998) Correlation of cytogenetic abnormalities with the outcome of patients with uveal melanoma. Cancer 83(2):354–359CrossRefPubMed

10.

Bronkhorst IH, Maat W, Jordanova ES, Kroes WG, Schalij-Delfos NE, Luyten GP, Jager MJ (2011) Effect of heterogeneous distribution of monosomy 3 on prognosis in uveal melanoma. Arch Pathol Lab Med 135(8):1042–1047CrossRefPubMed

11.

Damato BE, Dopierala JA, Coupland SE (2010) Genotypic profiling of 452 choroidal melanomas with multiplex ligation-dependent probe amplification. Clin Cancer Res 16(24):6083–6092CrossRefPubMed

12.

Coupland SE, Lake SL, Zeschnigk M, Damato BE (2013) Molecular pathology of uveal melanoma. Eye (Lond) 27(2):230–242CrossRef

13.

Coupland SE, Kalirai H, Ho V, Thornton S, Damato BE, Heimann H (2015) Concordant chromosome 3 results in paired choroidal melanoma biopsies and subsequent tumour resection specimens. Br J Ophthalmol 99(10):1444–1450CrossRefPubMed

14.

Eleuteri A, Damato B, Coupland SE, Taktak A (2012) Enhancing survival prognostication in patients with choroidal melanoma by integrating pathologic, clinical and genetic predictors of metastasis. Int J Biomed Eng Technol 8(1):18–35CrossRef

15.

DeParis SW, Taktak A, Eleuteri A, Enanoria W, Heimann H, Coupland SE, Damato B (2016) External validation of the liverpool uveal melanoma prognosticator online. Invest Ophthalmol Vis Sci 57(14):6116–6122CrossRefPubMed

16.

Onken MD, Worley LA, Ehlers JP, Harbour JW (2004) Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res 64(20):7205–7209CrossRefPubMedPubMedCentral

17.

Tschentscher F, Husing J, Holter T, Kruse E, Dresen IG, Jockel KH, Anastassiou G, Schilling H, Bornfeld N, Horsthemke B, Lohmann DR, Zeschnigk M (2003) Tumor classification based on gene expression profiling shows that uveal melanomas with and without monosomy 3 represent two distinct entities. Cancer Res 63(10):2578–2584PubMed

18.

Chang SH, Worley LA, Onken MD, Harbour JW (2008) Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis. Melanoma Res 18(3):191–200CrossRefPubMed

19.

Onken MD, Worley LA, Char DH, Augsburger JJ, Correa ZM, Nudleman E, Aaberg TM Jr., Altaweel MM, Bardenstein DS, Finger PT, Gallie BL, Harocopos GJ, Hovland PG, McGowan HD, Milman T, Mruthyunjaya P et al (2012) Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. Ophthalmology 119(8):1596–1603CrossRefPubMedPubMedCentral

20.

Coupland SE, Damato BE (2013) Molecular analysis of uveal melanoma. Ophthalmology 120(7):e50CrossRefPubMed

21.

Lake SL, Damato BE, Kalirai H, Dodson AR, Taktak AF, Lloyd BH, Coupland SE (2013) Single nucleotide polymorphism array analysis of uveal melanomas reveals that amplification of CNKSR3 is correlated with improved patient survival. Am J Pathol 182(3):678–687CrossRefPubMed

22.

Field MG, Harbour JW (2014) Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol 25(3):234–239CrossRefPubMedPubMedCentral

23.

Dono M, Angelini G, Cecconi M, Amaro A, Esposito AI, Mirisola V, Maric I, Lanza F, Nasciuti F, Viaggi S, Gualco M, Bandelloni R, Truini M, Coviello DA, Zupo S, Mosci C et al (2014) Mutation frequencies of GNAQ, GNA11, BAP1, SF3B1, EIF1AX and TERT in uveal melanoma: detection of an activating mutation in the TERT gene promoter in a single case of uveal melanoma. Br J Cancer 110(4):1058–1065CrossRefPubMedPubMedCentral

24.

Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA, Council ML, Matatall KA, Helms C, Bowcock AM (2010) Frequent mutation of BAP1 in metastasizing uveal melanomas. Science 330(6009):1410–1413CrossRefPubMedPubMedCentral

25.

Harbour JW, Roberson ED, Anbunathan H, Onken MD, Worley LA, Bowcock AM (2013) Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet 45(2):133–135CrossRefPubMedPubMedCentral

26.

Martin M, Masshofer L, Temming P, Rahmann S, Metz C, Bornfeld N, van de Nes J, Klein-Hitpass L, Hinnebusch AG, Horsthemke B, Lohmann DR, Zeschnigk M (2013) Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3. Nat Genet 45(8):933–936CrossRefPubMedPubMedCentral

27.

Robertson AG, Shih J, Yau C, Gibb EA, Oba J, Mungall KL, Hess JM, Uzunangelov V, Walter V, Danilova L, Lichtenberg TM, Kucherlapati M, Kimes PK, Tang M, Penson A, Babur O et al (2017) Integrative analysis identifies four molecular and clinical subsets in uveal melanoma. Cancer Cell 32(2):204. https://doi.org/10.1016/j.ccell.2017.07.003 CrossRefPubMed

28.

Van Raamsdonk CD, Bezrookove V, Green G, Bauer J, Gaugler L, O’Brien JM, Simpson EM, Barsh GS, Bastian BC (2009) Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 457(7229):599–602CrossRefPubMed

29.

Van Raamsdonk CD, Griewank KG, Crosby MB, Garrido MC, Vemula S, Wiesner T, Obenauf AC, Wackernagel W, Green G, Bouvier N, Sozen MM, Baimukanova G, Roy R, Heguy A, Dolgalev I, Khanin R et al (2010) Mutations in GNA11 in uveal melanoma. N Engl J Med 363(23):2191–2199CrossRefPubMedPubMedCentral

30.

Scholz SL, Moller I, Reis H, Susskind D, van de Nes JAP, Leonardelli S, Schilling B, Livingstone E, Schimming T, Paschen A, Sucker A, Murali R, Steuhl KP, Schadendorf D, Westekemper H, Griewank KG (2017) Frequent GNAQ, GNA11, and EIF1AX mutations in Iris melanoma. Invest Ophthalmol Vis Sci 58(9):3464–3470CrossRefPubMed

31.

Mudhar HS, Doherty R, Salawu A, Sisley K, Rennie IG (2013) Immunohistochemical and molecular pathology of ocular uveal melanocytoma: evidence for somatic GNAQ mutations. Br J Ophthalmol 97(7):924–928CrossRefPubMed

32.

Vader MJC, Madigan MC, Versluis M, Suleiman HM, Gezgin G, Gruis NA, Out-Luiting JJ, Bergman W, Verdijk RM, Jager MJ, van der Velden PA (2017) GNAQ and GNA11 mutations and downstream YAP activation in choroidal nevi. Br J Cancer 117(6):884–887CrossRefPubMed

33.

Luke JJ, Triozzi PL, McKenna KC, Van Meir EG, Gershenwald JE, Bastian BC, Gutkind JS, Bowcock AM, Streicher HZ, Patel PM, Sato T, Sossman JA, Sznol M, Welch J, Thurin M, Selig S et al (2015) Biology of advanced uveal melanoma and next steps for clinical therapeutics. Pigment Cell Melanoma Res 28(2):135–147CrossRefPubMed

34.

Feng X, Degese MS, Iglesias-Bartolome R, Vaque JP, Molinolo AA, Rodrigues M, Zaidi MR, Ksander BR, Merlino G, Sodhi A, Chen Q, Gutkind JS (2014) Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through a trio-regulated rho GTPase signaling circuitry. Cancer Cell 25(6):831–845CrossRefPubMedPubMedCentral

35.

Yu FX, Luo J, Mo JS, Liu G, Kim YC, Meng Z, Zhao L, Peyman G, Ouyang H, Jiang W, Zhao J, Chen X, Zhang L, Wang CY, Bastian BC, Zhang K et al (2014) Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP. Cancer Cell 25(6):822–830CrossRefPubMedPubMedCentral

36.

Kalirai H, Dodson A, Faqir S, Damato BE, Coupland SE (2014) Lack of BAP1 protein expression in uveal melanoma is associated with increased metastatic risk and has utility in routine prognostic testing. Br J Cancer 111(7):1373–1380CrossRefPubMedPubMedCentral

37.

Koopmans AE, Verdijk RM, Brouwer RW, van den Bosch TP, van den Berg MM, Vaarwater J, Kockx CE, Paridaens D, Naus NC, Nellist M, van Ijcken WF, Kilic E, de Klein A (2014) Clinical significance of immunohistochemistry for detection of BAP1 mutations in uveal melanoma. Mod Pathol 27(10):1321–1330CrossRefPubMed

38.

Griewank KG, van de Nes J, Schilling B, Moll I, Sucker A, Kakavand H, Haydu LE, Asher M, Zimmer L, Hillen U, Thompson JF, Scolyer RA, Schadendorf D, Murali R (2014) Genetic and clinico-pathologic analysis of metastatic uveal melanoma. Mod Pathol 27(2):175–183CrossRefPubMed

39.

Landreville S, Agapova OA, Matatall KA, Kneass ZT, Onken MD, Lee RS, Bowcock AM, Harbour JW (2012) Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma. Clin Cancer Res 18(2):408–416CrossRefPubMed

40.

Abdel-Rahman MH, Pilarski R, Cebulla CM, Massengill JB, Christopher BN, Boru G, Hovland P, Davidorf FH (2011) Germline BAP1 mutation predisposes to uveal melanoma, lung adenocarcinoma, meningioma, and other cancers. J Med Genet 48(12):856–859CrossRefPubMed

41.

Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, Cox NJ, Dogan AU, Pass HI, Trusa S, Hesdorffer M, Nasu M, Powers A, Rivera Z, Comertpay S, Tanji M et al (2011) Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genet 43(10):1022–1025CrossRefPubMedPubMedCentral

42.

Furney SJ, Pedersen M, Gentien D, Dumont AG, Rapinat A, Desjardins L, Turajlic S, Piperno-Neumann S, de la Grange P, Roman-Roman S, Stern MH, Marais R (2013) SF3B1 mutations are associated with alternative splicing in uveal melanoma. Cancer Discov 3(10):1122–1129CrossRefPubMedPubMedCentral

43.

Onken MD, Worley LA, Harbour JW (2008) A metastasis modifier locus on human chromosome 8p in uveal melanoma identified by integrative genomic analysis. Clin Cancer Res 14(12):3737–3745CrossRefPubMed

44.

Ehlers JP, Worley L, Onken MD, Harbour JW (2005) DDEF1 is located in an amplified region of chromosome 8q and is overexpressed in uveal melanoma. Clin Cancer Res 11(10):3609–3613CrossRefPubMed

45.

Laurent C, Valet F, Planque N, Silveri L, Maacha S, Anezo O, Hupe P, Plancher C, Reyes C, Albaud B, Rapinat A, Gentien D, Couturier J, Sastre-Garau X, Desjardins L, Thiery JP et al (2011) High PTP4A3 phosphatase expression correlates with metastatic risk in uveal melanoma patients. Cancer Res 71(3):666–674CrossRefPubMed

46.

Johansson P, Aoude LG, Wadt K, Glasson WJ, Warrier SK, Hewitt AW, Kiilgaard JF, Heegaard S, Isaacs T, Franchina M, Ingvar C, Vermeulen T, Whitehead KJ, Schmidt CW, Palmer JM, Symmons J et al (2016) Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. Oncotarget 7(4):4624–4631CrossRefPubMed

47.

Moore AR, Ceraudo E, Sher JJ, Guan Y, Shoushtari AN, Chang MT, Zhang JQ, Walczak EG, Kazmi MA, Taylor BS, Huber T, Chi P, Sakmar TP, Chen Y (2016) Recurrent activating mutations of G‑protein-coupled receptor CYSLTR2 in uveal melanoma. Nat Genet 48(6):675–680CrossRefPubMedPubMedCentral

48.

Krishna Y, McCarthy C, Kalirai H, Coupland SE (2017) Inflammatory cell infiltrates in advanced metastatic uveal melanoma. Hum Pathol 29(1):60–67

49.

Trolet J, Hupe P, Huon I, Lebigot I, Decraene C, Delattre O, Sastre-Garau X, Saule S, Thiery JP, Plancher C, Asselain B, Desjardins L, Mariani P, Piperno-Neumann S, Barillot E, Couturier J (2009) Genomic profiling and identification of high-risk uveal melanoma by array CGH analysis of primary tumors and liver metastases. Invest Ophthalmol Vis Sci 50(6):2572–2580CrossRefPubMed

50.

McCarthy C, Kalirai H, Lake SL, Dodson A, Damato BE, Coupland SE (2016) Insights into genetic alterations of liver metastases from uveal melanoma. Pigment Cell Melanoma Res 29(1):60–67CrossRefPubMed

51.

Meir T, Dror R, Yu X, Qian J, Simon I, Pe’er J, Chowers I (2007) Molecular characteristics of liver metastases from uveal melanoma. Invest Ophthalmol Vis Sci 48(11):4890–4896CrossRefPubMed

52.

Kenawy N, Lake SL, Coupland SE, Damato BE (2013) Conjunctival melanoma and melanocytic intra-epithelial neoplasia. Eye (Lond) 27(2):142–152CrossRef

53.

Triay E, Bergman L, Nilsson B, All-Ericsson C, Seregard S (2009) Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol 93(11):1524–1528CrossRefPubMed

54.

Damato B, Coupland SE (2008) Conjunctival melanoma and melanosis: a reappraisal of terminology, classification and staging. J Clin Exp Ophthalmol 36(8):786–795CrossRef

55.

Damato B, Coupland SE (2009) Management of conjunctival melanoma. Expert Rev Anticancer Ther 9(9):1227–1239CrossRefPubMed

56.

Jakobiec FA, Bhat P, Colby KA (2010) Immunohistochemical studies of conjunctival nevi and melanomas. Arch Ophthalmol 128(2):174–183CrossRefPubMed

57.

Esmaeli B, Roberts D, Ross M, Fellman M, Cruz H, Kim SK, Prieto VG (2012) Histologic features of conjunctival melanoma predictive of metastasis and death (an American Ophthalmological thesis). Trans Am Ophthalmol Soc 110:64–73PubMedPubMedCentral

58.

Pfeiffer ML, Ozgur OK, Myers JN, Peng A, Ning J, Zafereo ME, Thakar S, Thuro B, Prieto VG, Ross MI, Esmaeli B (2017) Sentinel lymph node biopsy for ocular adnexal melanoma. Acta Ophthalmol (Copenh) 95(4):e323–e328CrossRef

59.

Tuomaala S, Kivela T (2004) Metastatic pattern and survival in disseminated conjunctival melanoma: implications for sentinel lymph node biopsy. Ophthalmology 111(4):816–821CrossRefPubMed

60.

Anastassiou G, Heiligenhaus A, Bechrakis N, Bader E, Bornfeld N, Steuhl KP (2002) Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol 86(2):163–167CrossRefPubMedPubMedCentral

61.

Shields CL, Kaliki S, Al-Dahmash SA, Lally SE, Shields JA (2012) American Joint Committee on Cancer (AJCC) clinical classification predicts conjunctival melanoma outcomes. Ophthal Plast Reconstr Surg 28(5):313–323CrossRefPubMed

62.

Tuomaala S, Toivonen P, Al-Jamal R, Kivela T (2007) Prognostic significance of histopathology of primary conjunctival melanoma in Caucasians. Curr Eye Res 32(11):939–952CrossRefPubMed

63.

Gear H, Williams H, Kemp EG, Roberts F (2004) BRAF mutations in conjunctival melanoma. Invest Ophthalmol Vis Sci 45(8):2484–2488CrossRefPubMed

64.

Goldenberg-Cohen N, Cohen Y, Rosenbaum E, Herscovici Z, Chowers I, Weinberger D, Pe’er J, Sidransky D (2005) T1799A BRAF mutations in conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci 46(9):3027–3030CrossRefPubMed

65.

Griewank KG, Westekemper H, Murali R, Mach M, Schilling B, Wiesner T, Schimming T, Livingstone E, Sucker A, Grabellus F, Metz C, Susskind D, Hillen U, Speicher MR, Woodman SE, Steuhl KP et al (2013) Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas. Clin Cancer Res 19(12):3143–3152CrossRefPubMed

66.

Lake SL, Jmor F, Dopierala J, Taktak AF, Coupland SE, Damato BE (2011) Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes. Invest Ophthalmol Vis Sci 52(8):5598–5604CrossRefPubMed

67.

Beadling C, Jacobson-Dunlop E, Hodi FS, Le C, Warrick A, Patterson J, Town A, Harlow A, Cruz F 3rd, Azar S, Rubin BP, Muller S, West R, Heinrich MC, Corless CL (2008) KIT gene mutations and copy number in melanoma subtypes. Clin Cancer Res 14(21):6821–6828CrossRefPubMed

68.

Griewank KG, Murali R, Schilling B, Scholz S, Sucker A, Song M, Susskind D, Grabellus F, Zimmer L, Hillen U, Steuhl KP, Schadendorf D, Westekemper H, Zeschnigk M (2013) TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours. Br J Cancer 109(2):497–501CrossRefPubMedPubMedCentral

69.

Koopmans AE, Ober K, Dubbink HJ, Paridaens D, Naus NC, Belunek S, Krist B, Post E, Zwarthoff EC, de Klein A, Verdijk RM (2014) Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions. Invest Ophthalmol Vis Sci 55(9):6024–6030CrossRefPubMed

Titel: Okuläre Melanome
Ein „Update“
verfasst von: H. Kalirai
P. L. Müller
D. Jaehne
Prof. Dr. S. E. Coupland
Publikationsdatum: 16.10.2017
Verlag: Springer Medizin
Schlagwörter: Aderhautmelanom
Zielgerichtete Therapie
Melanom
Metastasen
Melanom
Okuläres Melanom
Erschienen in: Die Pathologie / Ausgabe 6/2017
Print ISSN: 2731-7188
Elektronische ISSN: 2731-7196
DOI: https://doi.org/10.1007/s00292-017-0389-3

Passend zum Thema

AGO-Leitlinie 2024: Update zu CDK4 & 6 Inhibitoren

Die Kommission Mamma der Arbeitsgemeinschaft Gynäkologische Onkologie (AGO) hat am 02. März 2024 ihre aktualisierten Empfehlungen präsentiert.[1,2] Welchen Stellenwert CDK4 & 6 Inhibitoren in der Therapie des Hormonrezeptor-positiven (HR+), HER2-negativen (HER2-) Mammakarzinoms haben, erfahren Sie hier im Update.

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

In der MONARCH-3-Studie erhielten Patientinnen mit fortgeschrittenem HR+, HER2- Brustkrebs Abemaciclib [1,a] in Kombination mit nicht-steroidalem Aromatasehemmer (nsAI). Die finalen Daten bestätigen den in früheren Analysen beobachteten Unterschied zugunsten der Kombinationstherapie. [2] Details dazu vom SABCS 2023.

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom

Es erwarten Sie praxisrelevante Patientenfälle, kompakte Studiendarstellungen, informative Experteninterviews sowie weitere spannende Inhalte rund um das HR+, HER2- Mammakarzinom.

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 6/2017

Mesotheliom

Lean-Management im Pathologielabor

Mitteilungen des Bundesverbandes Deutscher Pathologen e.V.

Tumoren der Sinnesorgane

Mitteilungen der Deutschen Gesellschaft für Pathologie

Retinoblastom und Retinozytom (Retinom)

Passend zum Thema

AGO-Leitlinie 2024: Update zu CDK4 & 6 Inhibitoren

Finale OS-Analyse der MONARCH-3-Studie vorgestellt

Die Bedeutung der CDK4 & 6 Inhibition beim HR+, HER2- Mammakarzinom